NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Other Non-current Assets
Long-term assets not reported separately.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 60.2% from a year ago
Other non-current assets stood at $535K at the end of Q1 FY2026, up 60.2% from a year earlier and up 111.5% from the prior quarter. Over 3 fiscal years it compounded at +146.9% a year.
Context
- Other non-current assets amounted to 4.5% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +60.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 316K USD
- Year-over-year change
- -9.5%
- 4-year CAGR
- +114.2%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 316K | -9.5% |
| FY2024 | 2024-12-31 | 349K | -19.0% |
| FY2023 | 2023-12-31 | 431K | +1952.4% |
| FY2022 | 2022-12-31 | 21K | +40.0% |
| FY2021 | 2021-12-31 | 15K | — |
Other Non-current Assets vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 other non-current assets of $535K is the 3rd highest of the 9 companies compared; the peer median is $317.09K.
- Its year-over-year change of +60.2% is the 4th highest of 9, against a peer median of -41.7%.
- Other non-current assets amounts to 4.5% of total assets for NRXP, versus a peer median of 0.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.57M | +388.0% | -59.8% | 0.8% | |
| Mar 2026 | $725K | -64.8% | -39.3% | 2.3% | |
| Mar 2026 | $535K | +60.2% | +146.9% | 4.5% | |
| Mar 2026 | $503K | +146.6% | -84.5% | 0.9% | |
| Mar 2026 | $320.29K | -18.7% | +46.8% | 1.5% | |
| Mar 2026 | $313.89K | -75.9% | +130.2% | 1.6% | |
| Mar 2026 | $267K | -84.1% | -25.0% | 0.2% | |
| Mar 2026 | $27K | +2700100.0% | — | 0.0% | |
| Jun 2026 | $0 | -100.0% | -84.6% | 0.0% | |
| Peer median (excluding NRXP) | $317.09K | -41.7% | -39.3% | 0.8% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.